Outcomes and safety of DAA treatment in HCV cirrhotic patients treated with Atezolizumab- Bevacizumab for hepatocellular carcinoma

IF 4 3区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY
L. Stella , G. Cabibbo , M. Iavarone , F. Piscaglia , F. Tovoli , F. Marra , C. Mazzarelli , R. Tortora , A. Aghemo , S. De Nicola , S. Bhoori , M. Pallozzi , A. Gasbarrini , L. Cerrito , F.R. Ponziani
{"title":"Outcomes and safety of DAA treatment in HCV cirrhotic patients treated with Atezolizumab- Bevacizumab for hepatocellular carcinoma","authors":"L. Stella ,&nbsp;G. Cabibbo ,&nbsp;M. Iavarone ,&nbsp;F. Piscaglia ,&nbsp;F. Tovoli ,&nbsp;F. Marra ,&nbsp;C. Mazzarelli ,&nbsp;R. Tortora ,&nbsp;A. Aghemo ,&nbsp;S. De Nicola ,&nbsp;S. Bhoori ,&nbsp;M. Pallozzi ,&nbsp;A. Gasbarrini ,&nbsp;L. Cerrito ,&nbsp;F.R. Ponziani","doi":"10.1016/j.dld.2025.01.047","DOIUrl":null,"url":null,"abstract":"<div><h3>Background and Aims</h3><div>Hepatitis C virus (HCV) infection is a critical driver of hepatocellular carcinoma (HCC) development and progression. Concurrent HCV treatment during systemic HCC therapy has not shown consistent benefits on survival and disease progression. This study aimed to evaluate safety and efficacy of Direct-Acting Antiviral (DAA) therapy in HCV-related HCC patients undergoing Atezolizumab-Bevacizumab (A/B), analysing its effects on overall survival (OS), time to progression (TTP), progression-free survival (PFS), liver decompensation rates.</div></div><div><h3>Method</h3><div>A total of 135 patients with HCV-related cirrhosis undergoing A/B treatment for HCC were enrolled from 2021 to 2024 and divided into groups based on HCV treatment status: an “active eradication” group (18 patients) who achieved sustained virological response (SVR) after DAA therapy concurrent with A/B treatment, a “prior eradication” group (95 patients) that reached SVR with DAAs or IFN-based regimens at least six months before starting A/B, and a “no eradication” group (22 patients) who did not obtain SVR at all.</div></div><div><h3>Results</h3><div>19 patients received SOF/VEL for 12 weeks achieving a 94.7% SVR rate, mostly due to elevated ALT and AST levels (94.4%). No adverse events (AEs) related to DAA therapy occurred during the treatment course.</div><div>The active eradication group demonstrated a significantly improved median OS that was not reached compared to the no eradication group (NA, 95% CI: 22.8–NA vs 20.0 months, 95% CI: 15.5–NA; p = 0.026). Regarding TTP, the active eradication group showed a median of 41.20 months (95% CI: 18.6– NA) compared to 21.3 months (95% CI: 5.13–NA) in no eradication group (p = 0.008). PFS results further supported the benefits of active eradication, with a median PFS of 41.17 months (95% CI: 22.80–NA) compared to 7.76 months (95% CI: 4.53–NA) in the no eradication group (p = 0.012). In contrast, the prior eradication group did not show significant survival benefits compared to the no eradication group for all outcomes. Liver decompensation rates did not differ significantly among groups (p &gt; 0.05).</div></div><div><h3>Conclusion</h3><div>DAA therapy was safe and effective in patients with unresectable HCC receiving A/B treatment. DAA therapy during A/B significantly improved OS, TTP, and PFS in patients with HCV-related HCC, likely enhancing the A/B treatment effect through immunomodulatory mechanisms. This is particularly relevant in settings where maximizing disease control is critical, such as downstaging in patients undergoing liver transplantation.</div></div>","PeriodicalId":11268,"journal":{"name":"Digestive and Liver Disease","volume":"57 ","pages":"Pages S24-S25"},"PeriodicalIF":4.0000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Digestive and Liver Disease","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1590865825000489","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background and Aims

Hepatitis C virus (HCV) infection is a critical driver of hepatocellular carcinoma (HCC) development and progression. Concurrent HCV treatment during systemic HCC therapy has not shown consistent benefits on survival and disease progression. This study aimed to evaluate safety and efficacy of Direct-Acting Antiviral (DAA) therapy in HCV-related HCC patients undergoing Atezolizumab-Bevacizumab (A/B), analysing its effects on overall survival (OS), time to progression (TTP), progression-free survival (PFS), liver decompensation rates.

Method

A total of 135 patients with HCV-related cirrhosis undergoing A/B treatment for HCC were enrolled from 2021 to 2024 and divided into groups based on HCV treatment status: an “active eradication” group (18 patients) who achieved sustained virological response (SVR) after DAA therapy concurrent with A/B treatment, a “prior eradication” group (95 patients) that reached SVR with DAAs or IFN-based regimens at least six months before starting A/B, and a “no eradication” group (22 patients) who did not obtain SVR at all.

Results

19 patients received SOF/VEL for 12 weeks achieving a 94.7% SVR rate, mostly due to elevated ALT and AST levels (94.4%). No adverse events (AEs) related to DAA therapy occurred during the treatment course.
The active eradication group demonstrated a significantly improved median OS that was not reached compared to the no eradication group (NA, 95% CI: 22.8–NA vs 20.0 months, 95% CI: 15.5–NA; p = 0.026). Regarding TTP, the active eradication group showed a median of 41.20 months (95% CI: 18.6– NA) compared to 21.3 months (95% CI: 5.13–NA) in no eradication group (p = 0.008). PFS results further supported the benefits of active eradication, with a median PFS of 41.17 months (95% CI: 22.80–NA) compared to 7.76 months (95% CI: 4.53–NA) in the no eradication group (p = 0.012). In contrast, the prior eradication group did not show significant survival benefits compared to the no eradication group for all outcomes. Liver decompensation rates did not differ significantly among groups (p > 0.05).

Conclusion

DAA therapy was safe and effective in patients with unresectable HCC receiving A/B treatment. DAA therapy during A/B significantly improved OS, TTP, and PFS in patients with HCV-related HCC, likely enhancing the A/B treatment effect through immunomodulatory mechanisms. This is particularly relevant in settings where maximizing disease control is critical, such as downstaging in patients undergoing liver transplantation.
求助全文
约1分钟内获得全文 求助全文
来源期刊
Digestive and Liver Disease
Digestive and Liver Disease 医学-胃肠肝病学
CiteScore
6.10
自引率
2.20%
发文量
632
审稿时长
19 days
期刊介绍: Digestive and Liver Disease is an international journal of Gastroenterology and Hepatology. It is the official journal of Italian Association for the Study of the Liver (AISF); Italian Association for the Study of the Pancreas (AISP); Italian Association for Digestive Endoscopy (SIED); Italian Association for Hospital Gastroenterologists and Digestive Endoscopists (AIGO); Italian Society of Gastroenterology (SIGE); Italian Society of Pediatric Gastroenterology and Hepatology (SIGENP) and Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). Digestive and Liver Disease publishes papers on basic and clinical research in the field of gastroenterology and hepatology. Contributions consist of: Original Papers Correspondence to the Editor Editorials, Reviews and Special Articles Progress Reports Image of the Month Congress Proceedings Symposia and Mini-symposia.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信